JP2004534730A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534730A5
JP2004534730A5 JP2002556226A JP2002556226A JP2004534730A5 JP 2004534730 A5 JP2004534730 A5 JP 2004534730A5 JP 2002556226 A JP2002556226 A JP 2002556226A JP 2002556226 A JP2002556226 A JP 2002556226A JP 2004534730 A5 JP2004534730 A5 JP 2004534730A5
Authority
JP
Japan
Prior art keywords
cancer
binding region
kit
sample
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002556226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534730A (ja
JP4564714B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/044782 external-priority patent/WO2002056022A2/en
Publication of JP2004534730A publication Critical patent/JP2004534730A/ja
Publication of JP2004534730A5 publication Critical patent/JP2004534730A5/ja
Application granted granted Critical
Publication of JP4564714B2 publication Critical patent/JP4564714B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002556226A 2000-11-27 2001-11-27 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 Expired - Lifetime JP4564714B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US25336100P 2000-11-27 2000-11-27
US25537000P 2000-12-13 2000-12-13
US25602700P 2000-12-15 2000-12-15
US25815700P 2000-12-22 2000-12-22
US25961501P 2001-01-03 2001-01-03
US26018601P 2001-01-05 2001-01-05
US26616901P 2001-02-02 2001-02-02
US26692901P 2001-02-06 2001-02-06
US27809301P 2001-03-23 2001-03-23
US28944401P 2001-05-07 2001-05-07
US29488701P 2001-05-31 2001-05-31
US29827201P 2001-06-14 2001-06-14
PCT/US2001/044782 WO2002056022A2 (en) 2000-11-27 2001-11-27 Diagnostics, drug screening and treatment for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009271611A Division JP5926474B2 (ja) 2000-11-27 2009-11-30 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法

Publications (3)

Publication Number Publication Date
JP2004534730A JP2004534730A (ja) 2004-11-18
JP2004534730A5 true JP2004534730A5 (enExample) 2005-12-22
JP4564714B2 JP4564714B2 (ja) 2010-10-20

Family

ID=27583824

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002556226A Expired - Lifetime JP4564714B2 (ja) 2000-11-27 2001-11-27 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2009271611A Expired - Lifetime JP5926474B2 (ja) 2000-11-27 2009-11-30 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2014205598A Expired - Lifetime JP6124856B2 (ja) 2000-11-27 2014-10-06 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2017013054A Expired - Lifetime JP6516778B2 (ja) 2000-11-27 2017-01-27 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009271611A Expired - Lifetime JP5926474B2 (ja) 2000-11-27 2009-11-30 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2014205598A Expired - Lifetime JP6124856B2 (ja) 2000-11-27 2014-10-06 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2017013054A Expired - Lifetime JP6516778B2 (ja) 2000-11-27 2017-01-27 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法

Country Status (7)

Country Link
US (3) US7700715B2 (enExample)
EP (4) EP2322929B1 (enExample)
JP (4) JP4564714B2 (enExample)
AT (1) ATE481640T1 (enExample)
CA (1) CA2430060C (enExample)
DK (1) DK2322929T3 (enExample)
WO (1) WO2002056022A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
AU9657901A (en) 2000-10-03 2002-04-15 Minerva Biotechnologies Corp Magnetic in situ dilution
JP4564714B2 (ja) * 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
AU2002252459A1 (en) * 2001-03-22 2002-10-08 Minerva Biotechnologies Corporation Customized therapeutics and in situ diagnostics
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
US20060280730A1 (en) * 2001-10-12 2006-12-14 Cedars-Sinai Medical Center Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
US20040180379A1 (en) * 2002-08-30 2004-09-16 Northwestern University Surface-enhanced raman nanobiosensor
AU2003262515A1 (en) 2002-09-19 2004-04-08 Nieland, John Mr Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
EP1594439A2 (en) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
WO2005007282A2 (en) * 2003-05-13 2005-01-27 Minerva Biotechnologies Corporation Storage and use of colloids
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
DK2363410T3 (en) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp ISOFORMER OF MUC1
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
WO2005094322A2 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
DK1875244T3 (en) * 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070224638A1 (en) * 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
WO2009042814A1 (en) * 2007-09-25 2009-04-02 Minerva Biotechnologies Corp. Early diagnosis and treatment of drug resistance in muc1-positive cancer
CN102239182B (zh) * 2008-10-06 2014-07-09 米纳瓦生物技术公司 Muc1*抗体
KR20140101876A (ko) 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
EA026732B1 (ru) * 2009-06-11 2017-05-31 Минерва Байотекнолоджиз Корпорейшн Способы культивирования стволовых клеток и клеток-предшественников
EP3065105B1 (en) * 2009-06-12 2020-04-29 Nikon Corporation Technique for determining the state of a cell aggregation, image processing program and image processing device using the technique, and method for producing a cell aggregation
JPWO2011013319A1 (ja) * 2009-07-31 2013-01-07 株式会社ニコン 細胞塊の成熟判定手法、この手法を用いた画像処理プログラム及び画像処理装置、並びに細胞塊の製造方法
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
JP5066615B2 (ja) 2011-01-31 2012-11-07 株式会社日立製作所 フェニルボロン酸基と特異的に結合するオリゴペプチド配列
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
WO2013059373A2 (en) 2011-10-17 2013-04-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
MX380864B (es) 2014-01-29 2025-03-12 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
CN104297442B (zh) * 2014-11-03 2016-08-17 天津中医药大学 内源性小分子物质在快速检测早期心脏毒性方面的应用
US11123366B1 (en) * 2014-12-15 2021-09-21 Children's Hospital Of Orange County Methods, materials, and systems for treating injuries to the central nervous system using light emitting nanoparticles
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
US10617773B2 (en) 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP6811489B2 (ja) * 2016-10-17 2021-01-13 学校法人慶應義塾 未分化幹細胞除去剤、及び未分化幹細胞除去方法
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
CN111875712A (zh) * 2020-07-31 2020-11-03 广东昭泰体内生物医药科技有限公司 一种增强型靶向muc1的嵌合抗原受体及其应用
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1504A (en) 1840-03-03 Mode osi constructing- bedsteads
US1997A (en) 1841-03-03 Improvement in the mode of rendering fabrics water-proof
US603173A (en) 1898-04-26 Motor
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5108933A (en) * 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
EP0369816A3 (en) * 1988-11-17 1990-09-12 The University Of Melbourne Monoclonal antibodies specific for human polymorphic epithelial mucin
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US5767135A (en) * 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
FR2746016B1 (fr) * 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
US6177393B1 (en) * 1996-12-12 2001-01-23 The Procter & Gamble Company Process for making tabletted detergent compositions
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
WO2000034783A1 (en) 1998-12-08 2000-06-15 Smithkline Beecham Corporation Methods of screening for agonists and antagonists of the hdpxu17 receptor
EP1147416B1 (en) * 1999-01-23 2013-05-29 Minerva Biotechnologies Corporation Assays involving colloids and non-colloidal structures
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
US6421389B1 (en) * 1999-07-16 2002-07-16 Time Domain Corporation Baseband signal converter for a wideband impulse radio receiver
DE60028996T2 (de) * 1999-11-12 2007-02-08 The Johns Hopkins University School Of Medicine Behandlung von krebs durch erhöhung des malonyl-coa-spiegels
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
EP1317278B1 (en) 2000-09-11 2009-11-11 Dana-Farber Cancer Institute, Inc. Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
AU2002248909A1 (en) 2000-11-15 2002-05-27 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
JP4564714B2 (ja) 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
JP2005508839A (ja) 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
JP2005501887A (ja) 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 癌の処置における組成物およびその使用
EP2329822A1 (en) 2001-09-05 2011-06-08 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP2006504630A (ja) 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
EP1536814A4 (en) 2002-07-03 2006-02-15 Immunogen Inc ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog

Similar Documents

Publication Publication Date Title
JP2004534730A5 (enExample)
JP2010106028A5 (enExample)
JP4896994B2 (ja) Ｂｃｌ−２レベルの上昇による癌の検出
Kestler et al. Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms
Krause et al. Rapid microfluidic immunoassays of cancer biomarker proteins using disposable inkjet-printed gold nanoparticle arrays
KR20100044307A (ko) 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
Muhammad Khyani et al. Detection of interleukins-6 and 8 in saliva as potential biomarkers of oral pre-malignant lesion and oral carcinoma: A breakthrough in salivary diagnostics in Pakistan.
EP2525227B1 (en) A method for detecting pancreatic cancer using the serological marker ULBP2
CN110456055A (zh) 一种检测ps外泌体的生物传感器及其制备方法
JP6847972B2 (ja) 大腸がん診断用組成物と診断マーカー検出方法
Jain et al. Small integrin-binding proteins as serum markers for prostate cancer detection
RU2008101660A (ru) Способ диагностики болезни альцгеймера
Selwyna et al. Development of electrochemical biosensor for breast cancer detection using gold nanoparticle doped CA 15-3 antibody and antigen interaction
Tang et al. Highly sensitive electrochemical immunosensor based on SiO2 nanospheres for detection of EGFR as colorectal cancer biomarker
Lee et al. A high-sensitivity cfDNA capture enables to detect the BRAF V600E mutation in papillary thyroid carcinoma
CN112595849B (zh) 用于早期食管癌筛查的血清学检测标志物及其应用
CN111579787B (zh) 一种用于早期食管鳞癌筛查的试纸条
Henderson et al. Enzyme measurements by mass: an interim review of the clinical efficacy of some mass measurements of prostatic acid phosphatase and the isoenzymes of creatine kinase
Karmakar et al. Protein Biomarkers and Its Applications in Oral Health
JP5211315B2 (ja) 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
CN107144688A (zh) Cd19阳性外泌体作为分子标记在制备肿瘤诊断试剂盒中的应用及试剂盒
CN113267626B (zh) 一种用于高危人群贲门腺癌早期筛查的试纸条
JP4628098B2 (ja) 肝細胞癌を診断する方法と組成物
US20090239255A1 (en) Odontogenic ameloblast-associated protein as a tumor biomarker
Arora et al. Electrochemical immunosensor based on NiO for CA 15–3 detection and agent-based modelling for treatment optimization